GSK stock slips after $2.2 billion RAPT deal — what investors watch before the open
New York, Jan 21, 2026, 04:20 EST — Premarket GSK plc’s U.S.-listed shares slipped 1.2% to $47.65 in light premarket trading Wednesday, following the announcement of a $2.2 billion acquisition and changes at its HIV joint venture. The RAPT Therapeutics acquisition marks the first big move by new CEO Luke Miels, coming as investors demand clearer plans from GSK on…